C. Of, . Government, and . Spain, European Commission under the 6th Framework Programme, Contract No. LSHC-CT-2006-018702 (GenoMEL); the European Commission under the 7th Framework Programme, Diagnoptics; the National Cancer Institute (NCI) of the U.S. National Institute of Health (NIH) (CA83115); and a grant from " Fundací o La MaratóMarat´Marató de TV3, Catalonia, Spain. Susan Puig's work was carried out at the Esther Koplowitz Center The authors received no financial compensation for authoring the manuscript, 201331.

A. E. Contributions-conception-mario, P. A. Lacouture, R. Ascierto, N. Dummer, S. Basset-seguin et al., Jonas Sokolof Provision of study material or patients Ketty Peris, Rainer Kunstfeld Collection and/or assembly of data Rainer Kunstfeld Data analysis and interpretation Axel Hauschild Final approval of manuscript, RF

A. Hauschild, The other authors indicated no financial relationships

R. 1. Macha, M. Batra, S. Ganti, and A. , Profile of vismodegib and its potential in the treatment of advanced basal cell carcinoma, Cancer Manag Res, vol.5, pp.197-203, 2013.

. Erivedge, Genentech USA, Inc.; 2015. 4. Medicines.co.uk. Erivedge 150 mg hard capsules: Summary of product characteristics Available at https, 2016.

M. Migden, A. Guminski, and R. Gutzmer, Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial, The Lancet Oncology, vol.16, issue.6, pp.716-728, 2015.
DOI : 10.1016/S1470-2045(15)70100-2

A. Sekulic, M. Migden, and A. Oro, Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma, New England Journal of Medicine, vol.366, issue.23, pp.2171-2179, 2012.
DOI : 10.1056/NEJMoa1113713

A. Sekulic, M. Migden, and K. Lewis, Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC, Journal of the American Academy of Dermatology, vol.72, issue.6, pp.1021-1027, 2015.
DOI : 10.1016/j.jaad.2015.03.021

A. Chang, J. Solomon, and J. Hainsworth, Expanded access study of patients with advanced basal??cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib, Journal of the American Academy of Dermatology, vol.70, issue.1, pp.60-69, 2014.
DOI : 10.1016/j.jaad.2013.09.012

M. Lacouture, J. Guillen, and R. Kudchadkar, Management of frequent vismodegib-related adverse events in patients with locally advanced basal cell carcinoma: RegiSONIC Disease Registry Study. Poster presented at the 74th Annual Meeting of the American Academy of Dermatology, 2016.

H. Sofen, K. Gross, and L. Goldberg, A phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma Vismodegib in patients with advanced basal cell carcinoma (STEVIE): A pre-planned interim analysis of an international, open-label trial, J Am Acad Dermatol Lancet Oncol, vol.7316, pp.99-105729, 2015.

R. Teperino, F. Aberger, and H. Esterbauer, Canonical and non-canonical Hedgehog signalling and the control of metabolism, Seminars in Cell & Developmental Biology, vol.33, pp.81-92, 2014.
DOI : 10.1016/j.semcdb.2014.05.007

D. Brennan, X. Chen, and L. Cheng, Noncanonical Hedgehog Signaling, Vitam Horm, vol.88, pp.55-72, 2012.
DOI : 10.1016/B978-0-12-394622-5.00003-1

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3513281

E. Epstein, Basal cell carcinomas: attack of the hedgehog, Nature Reviews Cancer, vol.14, issue.10, pp.743-754, 2008.
DOI : 10.1001/jama.294.6.681

D. Göppner and M. Leverkus, Basal Cell Carcinoma: From the Molecular Understanding of the Pathogenesis to Targeted Therapy of Progressive Disease, Journal of Skin Cancer, vol.6, issue.11
DOI : 10.1158/1535-7163.MCT-08-0586

L. Muzio, L. Gould, S. Low, J. Marsters, and J. Jr, Nevoid basal cell carcinoma syndrome (Gorlin syndrome) Discovery and preclinical development of vismodegib, Orphanet J Rare Dis Expert Opin Drug Discov, vol.39, issue.18, pp.32969-984, 2008.

G. Straface, T. Aprahamian, and A. Flex, Sonic hedgehog regulates angiogenesis and myogenesis during post-natal skeletal muscle regeneration, Journal of Cellular and Molecular Medicine, vol.26, issue.218
DOI : 10.1111/j.1582-4934.2008.00440.x

H. Yang, W. Cong, and J. Yoon, Vismodegib, an antagonist of hedgehog signaling, directly alters taste molecular signaling in taste buds, Cancer Medicine, vol.31, issue.2, pp.245-252, 2015.
DOI : 10.1002/cam4.350

A. Kumari, A. Ermilov, and B. Allen, Hedgehog pathway blockade with the cancer drug LDE225 disrupts taste organs and taste sensation, Journal of Neurophysiology, vol.113, issue.3, pp.1034-1040, 2015.
DOI : 10.1152/jn.00822.2014

B. St-jacques, H. Dassule, and I. Karavanova, Sonic hedgehog signaling is essential for hair development, Current Biology, vol.8, issue.19, pp.1058-1068, 1998.
DOI : 10.1016/S0960-9822(98)70443-9

URL : http://doi.org/10.1016/s0960-9822(98)70443-9

C. Chiang, R. Swan, and M. Grachtchouk, Essential Role forSonic hedgehogduring Hair Follicle Morphogenesis, Developmental Biology, vol.205, issue.1, pp.1-9, 1999.
DOI : 10.1006/dbio.1998.9103

N. Sato, P. Leopold, and R. Crystal, Induction of the hair growth phase in postnatal mice by localized transient expression of Sonic hedgehog, Journal of Clinical Investigation, vol.104, issue.7, pp.855-864, 1999.
DOI : 10.1172/JCI7691

R. Paladini, J. Saleh, and C. Qian, Modulation of Hair Growth with Small Molecule Agonists of the Hedgehog Signaling Pathway, Journal of Investigative Dermatology, vol.125, issue.4, pp.638-646, 2005.
DOI : 10.1111/j.0022-202X.2005.23867.x

L. Wang, Z. Liu, and L. Gambardella, Conditional Disruption of Hedgehog Signaling Pathway Defines its Critical Role in Hair Development and Regeneration, Journal of Investigative Dermatology, vol.114, issue.5, pp.901-908, 2000.
DOI : 10.1046/j.1523-1747.2000.00951.x

J. Lear, A. Guminski, and R. Gutzmer, A phase 2, randomized, double-blind study ofsonidegib (LDE225) in patients with advnaced basal cell carcinoma: the BOLT 18-month analysis. Presented at the 24th European Academy of Dermatology and Venereology Congress Hedgehog partial agonism drives Warburg-like metabolism in muscle and brown fat, Cell, vol.29151, pp.414-426, 2012.

S. Mathias, M. Chren, and R. Crosby, Reliability and validity of the Advanced Basal Cell Carcinoma Index (aBCCdex), British Journal of Dermatology, vol.143, issue.3, pp.713-719, 2015.
DOI : 10.1111/bjd.13877

A. Abdulla, P. Jones, and V. Pearce, Prevalence of Leg Cramps in the Elderly; Drug and Disease Associations, Age and Ageing, vol.26, issue.suppl 1, pp.494-496, 1999.
DOI : 10.1093/ageing/26.suppl_1.P9-a

C. Pohl, J. Happe, and T. Klockgether, Cooling improves the writing performance of patients with writer's cramp, Movement Disorders, vol.105, issue.6, pp.1341-1344, 2002.
DOI : 10.1002/mds.10251

T. Siegal, Muscle cramps in the cancer patient: Causes and treatment, Journal of Pain and Symptom Management, vol.6, issue.2, pp.84-91, 1991.
DOI : 10.1016/0885-3924(91)90522-6

F. Blyton, V. Chuter, and K. Walter, Non-drug therapies for lower limb muscle cramps Effect of calcium channel blockade on vismodegib-induced muscle cramps, Cochrane Database Syst Rev JAMA Dermatol, vol.1151, pp.8496-361132, 2012.

W. Voon and S. Sheu, Diltiazem for nocturnal leg cramps, Age and Ageing, vol.30, issue.1, pp.91-92, 2001.
DOI : 10.1093/ageing/30.1.91

N. Baltodano, B. Gallo, and D. Weidler, Verapamil vs Quinine in Recumbent Nocturnal Leg Cramps in the Elderly, Archives of Internal Medicine, vol.148, issue.9, pp.1969-1970, 1988.
DOI : 10.1001/archinte.1988.00380090055015

M. Serrao, P. Rossi, and P. Cardinali, Gabapentin Treatment for Muscle Cramps: An Open-Label Trial, Clinical Neuropharmacology, vol.23, issue.1
DOI : 10.1097/00002826-200001000-00008

P. Chan, T. Huang, and Y. Chen, Randomized, double-blind, placebo-controlled study of the safety and efficacy of vitamin B complex in the treatment of nocturnal leg cramps in elderly patients with hypertension Naftidrofuryl treatment for rest cramp, J Clin Pharmacol Postgrad Med J, vol.3869, pp.1151-1154, 1993.

A. Weil, G. Ruoff, and S. Nalamachu, Efficacy and Tolerability of Cyclobenzaprine Extended Release for Acute Muscle Spasm: A Pooled Analysis, Postgraduate Medicine, vol.7, issue.9, pp.158-169, 2010.
DOI : 10.3810/pgm.2010.07.2182

R. Baldinger, H. Katzberg, M. Weber, A. Khan, and Y. So, Treatment for cramps in amyotrophic lateral sclerosis/motor neuron disease US Food and Drug Administration Qualaquin (quinine sulfate): New riskevaluation and mitigation strategy -risk of serious hematological reactions Assessment: symptomatic treatment for muscle cramps (an evidence-based review), Cochrane Database Syst Rev Neurology, vol.4, issue.74, pp.4157-47691, 2010.

K. Syrjala, J. Yi, and S. Artherholt, Measuring musculoskeletal symptoms in cancer survivors who receive hematopoietic cell transplantation, Journal of Cancer Survivorship, vol.57, issue.3, pp.225-235, 2010.
DOI : 10.1007/s11764-010-0126-x

L. Huang and H. Wang, Taste bud homeostasis in health, disease, and aging, Available Chem Senses, vol.39, pp.3-16, 2014.

S. Rawal, H. Hoffman, and K. Bainbridge, Prevalence and Risk Factors of Self-Reported Smell and Taste Alterations: Results from the 2011???2012 US National Health and Nutrition Examination Survey (NHANES), Chemical Senses, vol.41, issue.1, pp.69-76, 2016.
DOI : 10.1093/chemse/bjv057

A. Hovan, P. Williams, and P. Stevenson-moore, A systematic review of dysgeusia induced by cancer therapies, Supportive Care in Cancer, vol.66, issue.5, pp.1081-1087, 2010.
DOI : 10.1007/s00520-010-0902-1

E. Gamper, A. Zabernigg, and L. Wintner, Coming to Your Senses: Detecting Taste and Smell Alterations in Chemotherapy Patients. A Systematic Review, Journal of Pain and Symptom Management, vol.44, issue.6, pp.880-895, 2012.
DOI : 10.1016/j.jpainsymman.2011.11.011

L. Barlow, Progress and renewal in gustation: new insights into taste bud development, Development, vol.142, issue.21, pp.3620-3629, 2015.
DOI : 10.1242/dev.120394

L. Moigne, M. Saint-jean, M. Jirka, and A. , Dysgeusia and weight loss under treatment with vismodegib: benefit of nutritional management, Supportive Care in Cancer, vol.99, issue.4, pp.1689-1695, 2016.
DOI : 10.1007/s00520-015-2932-1

S. Schiffman, E. Sattely-miller, and E. Taylor, Combination of flavor enhancement and chemosensory education improves nutritional status in older cancer patients, J Nutr Health Aging, vol.11, pp.439-454, 2007.

S. Heckmann, P. Hujoel, and S. Habiger, Zinc gluconate in the treatment of dysgeusia?a randomized clinical trial Does zinc sulfate prevent therapy-induced taste alterations in head and neck cancer patients? Results of phase III double-blind, placebo-controlled trial from the North Central Cancer Treatment Group (N01C4), J Dent Res Int J Radiat Oncol Biol Phys, vol.8467, issue.60, pp.35-381318, 2005.

J. Ferguson, S. Hannam, and R. Toholka, Hair loss and Hedgehog inhibitors: a class effect?, British Journal of Dermatology, vol.170, issue.2 Suppl. 1, pp.262-264, 2015.
DOI : 10.1111/bjd.13619

T. Fischer, S. Schmidt, and B. Strauss, Hairdex, Der Hautarzt, vol.52, issue.3, pp.219-2272180, 2001.
DOI : 10.1007/s001050051293

S. Alkeraye, C. Maire, and E. Desmedt, Persistent alopecia induced by vismodegib, British Journal of Dermatology, vol.129, issue.6, pp.1671-1672, 2015.
DOI : 10.1111/bjd.13630

K. Fearon, F. Strasser, and S. Anker, Definition and classification of cancer cachexia: an international consensus, Spathis A, Fife K, Blackhall F et al. Modafinil for the treatment of fatigue in lung cancer: Results of a placebo-controlled, double-blind, pp.489-495, 1968.
DOI : 10.1016/S1470-2045(10)70218-7

K. Ruddy, D. Barton, and C. Loprinzi, Laying to Rest Psychostimulants for Cancer-Related Fatigue?, Journal of Clinical Oncology, vol.32, issue.18, pp.1865-1867, 2014.
DOI : 10.1200/JCO.2014.55.8353

E. Smets, B. Garssen, and B. Bonke, The multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue, Journal of Psychosomatic Research, vol.39, issue.3
DOI : 10.1016/0022-3999(94)00125-O

J. Bower, K. Bak, and A. Berger, Screening, assessment, and management of fatigue in adult survivors of cancer, of Clinical Oncology clinical practice guideline adaptation

M. Russell, R. Cowan, and R. Harman, National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology Antiemesis. Version 2 Available at http:// www.nccn.org/professionals/physician_gls/pdf/ antiemesis.pdf. Accessed, J Clin Oncol, vol.32, pp.1840-1850, 1973.

L. Spicer, S. Sudo, and P. Aad, A novel role for hedgehog proteins in stimulating proliferation and steroidogenesis of theca cells Amenorrhea or irregular menses in patients treated with vismodegib. Presented at the 2014 Winter Clinical Dermatology Conference Kona Coast, HI. 76 Development of the National Cancer Institute's patientreported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) MIKIE: A randomized, double-blind, regimen-controlled, phase II, multicenter study to assess the efficacy and safety of two different vismodegib regimens in patients with multiple basal cell carcinomas, Presented at the 50th Annual Meeting of the MT et al. A phase II study to assess vismodegib in the neoadjuvant treatment of locally advanced basal cell carcinoma (laBCC): The Vismodegib Neoadjuvant (VISMONEO) study. Presented at the 50th Annual Meeting of the, pp.329-339, 2009.

A. Chang, K. Lewis, and A. St, Safety and efficacy of vismodegib in elderly patients: analysis of the ERIVANCE BCC and expanded access studies. Presented at the Third Annual World Cutaneous Malignancies Congress, 2014.